A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
Electrocardiographic (ECG) assessment of patients with acute coronary syndromes (ACS) in the PLATO trial confirms that those receiving ticagrelor are more likely to experience ventricular pauses than ...
A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...
LOS ANGELES, CA—Among medically managed patients with acute coronary syndromes (ACS) but no ST-segment elevation, prasugrel is associated with lower platelet reactivity than clopidogrel, irrespective ...
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
August 29, 2010 (Stockholm, Sweden) — Two genetic substudies of the large pivotal trials of the new antiplatelet agents ticagrelor (Brilinta, AstraZeneca) and prasugrel (Effient, Lilly) confirm that ...
Morning Overview on MSN
People on Ozempic shed muscle along with fat, so doctors now push strength training
Millions of adults taking semaglutide or tirzepatide are losing significant weight, but clinical trial data confirm they are ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results